Skip to main content

28.11.2018 | Review Article | Ausgabe 1/2019 Open Access

Forensic Toxicology 1/2019

The search for the “next” euphoric non-fentanil novel synthetic opioids on the illicit drugs market: current status and horizon scanning

Forensic Toxicology > Ausgabe 1/2019
Kirti Kumari Sharma, Tim G. Hales, Vaidya Jayathirtha Rao, Niamh NicDaeid, Craig McKenzie



A detailed review on the chemistry and pharmacology of non-fentanil novel synthetic opioid receptor agonists, particularly N-substituted benzamides and acetamides (known colloquially as U-drugs) and 4-aminocyclohexanols, developed at the Upjohn Company in the 1970s and 1980s is presented.


Peer-reviewed literature, patents, professional literature, data from international early warning systems and drug user fora discussion threads have been used to track their emergence as substances of abuse.


In terms of impact on drug markets, prevalence and harm, the most significant compound of this class to date has been U-47700 (trans-3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide), reported by users to give short-lasting euphoric effects and a desire to re-dose. Since U-47700 was internationally controlled in 2017, a range of related compounds with similar chemical structures, adapted from the original patented compounds, have appeared on the illicit drugs market. Interest in a structurally unrelated opioid developed by the Upjohn Company and now known as BDPC/bromadol appears to be increasing and should be closely monitored.


International early warning systems are an essential part of tracking emerging psychoactive substances and allow responsive action to be taken to facilitate the gathering of relevant data for detailed risk assessments. Pre-emptive research on the most likely compounds to emerge next, so providing drug metabolism and pharmacokinetic data to ensure that new substances are detected early in toxicological samples is recommended. As these compounds are chiral compounds and stereochemistry has a large effect on their potency, it is recommended that detection methods consider the determination of configuration.

Unsere Produktempfehlungen

e.Med Interdisziplinär


Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Über diesen Artikel

Weitere Artikel der Ausgabe 1/2019

Forensic Toxicology 1/2019 Zur Ausgabe

Neu im Fachgebiet Rechtsmedizin

14.03.2019 | Originalien | Ausgabe 2/2019

Medikamentennachweise bei bayerischen Altenheimbewohnern – eine rechtsmedizinische Analyse

Erste Ergebnisse aus Screeninguntersuchungen an Urinproben

07.03.2019 | Mammakarzinom | CME | Ausgabe 2/2019

Update der S3-Leitlinie Mammakarzinom

Was gibt es Neues für Pathologen?

21.02.2019 | Schwerpunkt: Neuropathologie | Ausgabe 2/2019

Neuropathologie der Medulloblastome und anderer embryonaler Tumoren des ZNS

Präzisierung der Diagnostik durch Integration genetischer Marker